Mexico is making proactive and systematic strides towards shaping the future of the pharmaceutical industry within the country and ambitiously across the entire region.
The “Estrategia de Certidumbre Regulatoria 2022-2030” (Regulatory Certainty Strategy) was recently presented by COFEPRIS. This well-defined strategy ultimately aims to enhance access to therapies in Latin America. This strategy recognizes the need for local market growth and emphasizes the importance of fostering interconnections within the region, across the continent, and globally.
The Mexican edition of the forum highlights investment as a crucial catalyst for promising growth, elucidates the investment sector’s interests and concerns, and provides proactive measures to navigate the upcoming COFEPRIS-defined scenario effectively.
Industry Executives from Latam
- Analytical science
- Regulatory compliance
- Quality Control
- Clinical immunology
- Scientific Affairs
- Business Development
Previous Speaker Board
Market Access & Pricing, Institutional Sales, Government Affairs & Policy HEAD
Maria Concepcion Prieto Yerro
CHMP committee member
Patricia Socualaya Sotomayor
Chief Officer at Biological Product Unit
Juan Pablo Acosta Martinez
Business Development Manager Biosimilars and Senior Application Specialist Purification
Program in 2022
Quality and Integrity of Biopharmaceutical Products Within Production Processes
How to ensure the safety of biotech products within Production processes? Experts sharing their point of view
Commercial Measures for Biosimilars in the LatAm Markets
Commercial strategies and market dynamics to ensure the promotion of biosimilars uptake in Mexico and LatAm
Collaborative: Reference Authorities’ Updates and Actions Towards Regulation for Biosimilars
Stay on top of the newest regulations and tendencies led by reference authorities on biosimilars regulatory frameworks
Biosimilars: Global Innovation and Competitiveness
How to innovate in the biosimilars industry and highly competitive markets?
Sponsors in 2022
We are a vibrant science and technology company. Science is at the heart of everything we do, it drives the discoveries we make and the technologies we create. For more than 350 years, curiosity has been driving us to deliver excellence to patients and customers – and to imagine the future.
Agilent is a leader in life sciences, diagnostics and applied chemical markets. The company provides laboratories worldwide with instruments, services, consumables, applications and expertise, enabling customers to gain the insights they seek. Agilent’s expertise and trusted collaboration give them the highest confidence in our solutions.
Pall associates around the world are unified by a singular drive: to solve our customers’ biggest filtration, separation and purification challenges. And, in doing so, advance health, safety and environmentally responsible technologies.
Our industry-leading technologies and solutions are at work in countless applications, safeguarding health, protecting critical operating assets, improving product quality, and minimizing emissions and waste.
Our Life Sciences and Industrial teams bring focused expertise to a diverse range of customers across multiple industries, including biotechnology, pharmaceutical, medical, food and beverage, laboratory, microelectronics, aerospace, fuels, petrochemical, chemical, automotive and power generation .
Cytiva is a global provider of technologies and services that help advance and accelerate the development and production of therapeutic products. Promoting training, speed and efficiency for research and production workflows, allowing the delivery of innovative medicines to patients.
The Sartorius Group is a leading international partner of life science research and the biopharmaceutical industry. With innovative laboratory instruments and consumables, the Group’s Lab Products & Services Division concentrates on serving the needs of laboratories performing research and quality control at pharma and biopharma companies and those of academic research institutes. The Bioprocess Solutions Division with its broad product portfolio focusing on single-use solutions helps customers to manufacture biotech medications and vaccines safely and efficiently. The Group has been annually growing by double digits on average and has been regularly expanding its portfolio by acquisitions of complementary technologies. In fiscal 2019, the company earned sales revenue of some 1.83 billion euros according to preliminary figures. At the end of 2019, more than 9,000 people work at the Group’s approximately 60 manufacturing and sales sites, serving customers around the globe.
We develop alliances with pharmaceutical companies, using Terumo technology to develop, manufacture and supply solutions to injectable drug delivery challenges. We pride ourselves on offering a portfolio of products and services for the pharmaceutical industry. By anticipating trends and maintaining a constant dialogue, we provide a first class customer experience.
Amgen is committed to unlocking the potential of biology for patients suffering from serious illnesses by discovering, developing, manufacturing and delivering innovative human therapeutics. This approach begins by using tools like advanced human genetics to unravel the complexities of disease and understand the fundamentals of human biology.
With 60+ dedicated scientists and support personal, UDIBI is a third-party laboratory authorized by the Mexican Regulatory Agency (COFEPRIS) to conduct analytical services for the pharmaceutical and medical devices industries. We also provide consulting services on antibody engineering and development of antibody-based therapeutics. With the support from government and private investment we have developed a portfolio of biotherapeutics that includes a product in the market and several therapeutic antibodies in diverse phases of discovery, optimization and preclinical development. In response to COVID-19 pandemic, UDIBI developed and commercializes the only 100% Mexican diagnostic kit to detect anti-SARS-CoV-2 antibodies with approval by COFEPRIS for commercialization in Mexico.